Notícias

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous day.

Gene-editing biotech targets up to $242.7 million valuation, with initial ASCVD trial data expected in 2027.

Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index shedding 1.1% and t

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

Investors have flocked to Eli Lilly for exposure to the high-growth weight loss drug market.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.

(Bloomberg) -- The peptide boom has all the markings of a mainstream wellness craze: podcast evangelists, celebrity converts and a billion-dollar market promising shortcuts to weight loss, muscle gain and a longer life. One major hurdle: actually buying them.Most Read from BloombergUS Strikes Iran in Escalating Campaign After Troops KilledThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsTrump Silent So Far on

ARKG sold 1.12 million ATAI shares last week but still held 3.19 million shares as of Friday.

Investors rotated into biotech, cybersecurity and insurance stocks with stronger growth prospects and earnings strength.

Maybe you should, too.

All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.

Eli Lilly stock has delivered a 406.3% return over the past five years, yet its latest valuation checks point to an unusual tension as the Discounted Cash Flow (DCF) intrinsic value suggests the shares trade at a discount while the broader scorecard still leans expensive. A roughly 5x gain over five years can signal that a lot of optimism is already reflected in Eli Lilly’s share price, putting more focus on what investors are paying for that growth story today. Expectations tied to obesity,...

Viking's latest program seeks to push the envelope in weight loss efficacy.

There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.

The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.

Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the

Novo Nordisk is finally getting one up on its biggest rival.

Omada, an Eli Lilly partner, has soared more than 118% in just a few months, moving up the right side of a new base.

Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.

Find insight on Eli Lilly, GSK, Intuitive Surgical and more in the latest Market Talks covering the Health Care sector.

Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GL

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders.

Big pharma is making a big bet that a DMT nasal spray could succeed where daily Prozac pills fall short.

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC)'s acquisition by Eli Lilly for up to $3.8 billion reinforces growing interest from large pharmaceutical companies in psychedelic-based therapies, according to analysts at Jefferies, who believe that the deal reflects increasing momentum driven by...

Companies In The Article Are:ASTS,ATAI,LLY,USB,CFG

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.